The Medical and Surgical Practice of NaProTECHNOLOGY, 335-340, 2004
Chapter 27: Cooperative Progesterone and Estrogen Replacement
Author affiliations
- Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska. ROR
Abstract
Cooperative progesterone and estrogen replacement therapy administers bioidentical hormones in precise synchrony with the woman's CrMS-identified Peak day -- beginning progesterone at P+2 or P+3 and continuing through the luteal phase -- to augment deficient corpus luteum output rather than override the cycle with suppressive dosing. Serial serum progesterone across post-Peak days guides dose titration, and the approach is applied to luteal phase deficiency, recurrent miscarriage, premenstrual syndrome, and postpartum depression while preserving ovulatory function and fertility.
Topics
NaProTECHNOLOGY > Cooperative Hormone Replacement > CPRT and CERTReproductive Endocrinology > Luteal Phase Dysfunction > Progesterone and Estradiol SupportFertility Awareness > Creighton Model > Peak Day Ovulation TimingMenstrual Cycle > Cycle Regulation > Postovulatory Phase TargetingNaProTECHNOLOGY > Corpus Luteum > HCG Luteal Support
Cite this article
Hilgers, T. W. (2004). Chapter 27: Cooperative Progesterone and Estrogen Replacement. *The Medical and Surgical Practice of NaProTECHNOLOGY*, 335-340.
Hilgers TW. Chapter 27: Cooperative Progesterone and Estrogen Replacement. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:335-340.
Hilgers, T. W. "Chapter 27: Cooperative Progesterone and Estrogen Replacement." *The Medical and Surgical Practice of NaProTECHNOLOGY*, 2004, pp. 335-340.